ATTO insider filings
Attovia Therapeutics, Inc. — 20 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-08. Screen ATTO transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 6 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 2 filings by 9 insiders — 1,170,000 shares, $20,570,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 46 legs across 2 filings by 9 insiders — 211,614 shares, $4,503,315 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: purchase of 500,000 shares @ $17.00 ($8,500,000) by WALSH COLIN, filed 2026-08-28.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC & GOLDMAN SACHS & CO. LLC & GOLDMAN SACHS ASSET MANAGEMENT, L.P. & Broad Street Principal Investments, L.L.C. & WSLS OFFSHORE INVESTMENTS, SLP & West Street Life Sciences I, L.P. & WSLS EMP OFFSHORE INVESTMENTS, L.P. & WSLS EMP ONSHORE INVESTMENTS, L.P. | 1 | 2 legs · 585,000 sh · $10,285,000 | 23 legs · 105,807 sh · $2,251,658 | 10 |
| WALSH COLIN — Director | 1 | 2 legs · 585,000 sh · $10,285,000 | 23 legs · 105,807 sh · $2,251,658 | 10 |
| Chan Steven — Chief Financial Officer | 2 | — | — | 1 |
| Fu Tao — President and CEO, Director | 2 | — | — | 1 |
Recent insider filings — Attovia Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-08 | 4/A | Chan Steven — Chief Financial Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-10-08 | 4/A | Fu Tao — President and CEO, Director | Grant/award (A): 538,300 (derivative) @ $0 | EDGAR |
| 2026-10-08 | 3/A | Fu Tao — President and CEO, Director | Holdings only — no transactions reported | EDGAR |
| 2026-10-08 | 3/A | Chan Steven — Chief Financial Officer | Holdings only — no transactions reported | EDGAR |
| 2026-08-28 | 4/A | WALSH COLIN — Director | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +29 more | EDGAR |
| 2026-08-28 | 4/A | GOLDMAN SACHS GROUP INC GOLDMAN SACHS & CO. LLC GOLDMAN SACHS ASSET MANAGEMENT, L.P. Broad Street Principal Investments, L.L.C. WSLS OFFSHORE INVESTMENTS, SLP West Street Life Sciences I, L.P. WSLS EMP OFFSHORE INVESTMENTS, L.P. WSLS EMP ONSHORE INVESTMENTS, L.P. | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +29 more | EDGAR |
| 2026-08-13 | 4 | WALSH COLIN — Director | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +23 more | EDGAR |
| 2026-08-13 | 4 | GOLDMAN SACHS GROUP INC GOLDMAN SACHS & CO. LLC GOLDMAN SACHS ASSET MANAGEMENT, L.P. Broad Street Principal Investments, L.L.C. WSLS OFFSHORE INVESTMENTS, SLP West Street Life Sciences I, L.P. WSLS EMP OFFSHORE INVESTMENTS, L.P. WSLS EMP ONSHORE INVESTMENTS, L.P. | Purchase (P): 85,000 @ $21 · Sale (S): 988 @ $22.03 · Sale (S): 447 @ $21.87 · Sale (S): 1,332 @ $22.03 · Sale (S): 200 @ $22.05 · Sale (S): 1,556 @ $22.06 · +23 more | EDGAR |
| 2026-08-10 | 4 | Deep Track Biotechnology Master Fund, Ltd. — 10% owner Deep Track Capital, LP — 10% owner KROIN DAVID — 10% owner | Conversion (C): 1,957,138 · Conversion (C): 18,181,818 (derivative) @ $0 | EDGAR |
| 2026-08-10 | 4 | venBio Global Strategic Fund IV, L.P. — 10% owner | Conversion (C): 2,311,870 · Conversion (C): 821,998 · Conversion (C): 665,147 · Purchase (P): 382,352 @ $17 · Conversion (C): 21,477,273 (derivative) @ $0 · Conversion (C): 7,636,362 (derivative) @ $0 · +1 more | EDGAR |
| 2026-08-07 | 4 | Redmile Group, LLC — 10% owner Green Jeremy — 10% owner Redmile Biopharma Investments III, L.P. — 10% owner | Conversion (C): 782,854 · Purchase (P): 200,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 782,854 (derivative) | EDGAR |
| 2026-08-07 | 4 | Sanofi — 10% owner | Conversion (C): 782,855 · Purchase (P): 300,000 @ $17 · Conversion (C): 782,855 (derivative) | EDGAR |
| 2026-08-06 | 4 | Frazier Life Sciences XI, L.P. — 10% owner FHMLS XI, L.P. — 10% owner FHMLS XI, L.L.C. — 10% owner | Conversion (C): 1,749,192 · Conversion (C): 1,590,175 · Conversion (C): 1,189,940 · Conversion (C): 961,322 · Purchase (P): 588,235 @ $17 · Conversion (C): 16,250,000 (derivative) @ $0 · +3 more | EDGAR |
| 2026-08-06 | 4 | Odrowaz Zaneta — Chief Business Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | GOLD MITCHELL — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | You Angie — Director | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Attovia Therapeutics, Inc. — Chief Financial Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Chen Hubert — Chief Medical Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Veiby Petter — Chief Scientific Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-08-06 | 4 | Attovia Therapeutics, Inc. — President and CEO, Director | Grant/award (A): 538,300 (derivative) @ $0 | EDGAR |
Recent 8-K events — Attovia Therapeutics, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-09 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events | EDGAR |
| 2026-09-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Attovia Therapeutics, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-297452 (S-1) — latest: Final prospectus (424B4), filed 2026-08-05
GET https://api.filingpulse.io/v1/insider-trades?ticker=ATTO returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs